This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Santo Tomas LH, Loberiza FR, Klein JP, Layde PM, Lipchik RJ, Douglas Rizzo et al. Risk factors for bronchiolitis obliterans in allogenic hematopoietic stem cell transplantation for leukemia. Chest 2005; 128: 153–161.
Dudek AZ, Mahaseth H, DeFor TE, Weisdorf DJ . Bronchiolitis obliterans in chronic graft-versus-host disease: analysis of risk factors and treatment outcomes. Biol Blood Marrow Transplant 2003; 9: 657–666.
Chien JW, Martin PJ, Gooley TA, Flowers ME, Heckbert W, Nichols G et al. Airflow obstruction after myeloablative allogenic hematopoietic stem cell transplantation. Am J Respir Crit Care Med 2003; 168: 208–214.
Chien JW, Martin PJ, Flowers ME, Nichols WG, Clark JG . Implications of early airflow decline after myeloablative allogenic stem cell transplantation. Bone Marrow Transplant 2004; 33: 759–764.
Vos R, Vanaudenaerde BM, Ottevaere A, Verleden SE, De Vleeschauwer SI, Willem-Widyastuti A et al. Long-term azithromycin therapy for bronchiolitis obliterans syndrome: divide and conquer? J Heart Lung Transplant 2010; 29: 1358–1368.
Vos R, Vanaudenaerde BM, Verleden SE, De Vleeschauwer SI, Willems-Widyastuti A, Van Raemdonck DE et al. A randomized placebo-controlled trial of azithromycin to prevent chronic rejection after lung transplantation. Eur Respir J 2011; 371: 164–172.
Majhail NS, Rizzo JD, Lee SJ, Aljurf M, Atsuta Y, Bonfim C et al. Center for International Blood and Marrow Transplant Research (CIBMTR); American Society for Blood and Marrow Transplantation (ASBMT); European Group for Blood and Marrow Transplantation (EBMT); Asia-Pacific Blood and Marrow Transplantation Group (APBMT); Bone Marrow Transplant Society of Australia and New Zealand (BMTSANZ); East Mediterranean Blood and Marrow Transplantation Group (EMBMT); Sociedade Brasileira de Transplante de Medula Ossea (SBTMO). Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012; 18: 348–371.
Acknowledgements
The authors would like to thank the BSBMT for sponsoring the study and the data managers and transplant physicians at the participating centres for providing the data: Dr A Peniket, Director of Bone Marrow Transplantation, Churchill Hospital, Oxford; Dr B Shaw, Institute of Cancer Research, Royal Marsden Hospital, London; Prof J Apperley, data manager F O’Boyle, Hammersmith Hospital, London; Dr T Littlewood, Oxford Radcliffe Hospitals, Oxford; Dr K Wilson, data manager S Nicholas, Cardiff University School of Medicine, Cardiff; Dr K Orchard, data manager C Hurlock, Southampton General Hospital, Southampton; Prof G Jackson, data manager L McNally, Freeman Road Hospital, Newcastle; Dr J Snowden, data manager A Sharma and B Holt, Sheffield Teaching Hospitals, Sheffield.
Author information
Authors and Affiliations
Consortia
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Dharmagunawardena, R., Pearce, R., Thomas, G. et al. A retrospective multi-centre study of the effects of allogeneic haematopoietic SCT on pulmonary function. Bone Marrow Transplant 49, 1442–1443 (2014). https://doi.org/10.1038/bmt.2014.154
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2014.154